Welcome to our dedicated page for ALONX news (Ticker: ALONX), a resource for investors and traders seeking the latest updates and insights on ALONX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALONX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALONX's position in the market.
Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), a biotechnology company focused on innovative oncology drugs, has announced its financial agenda for 2022. Key dates include: Full-year 2021 results on March 30, 2022; Shareholders’ general meeting on May 12, 2022; and Half-year 2022 results on July 28, 2022. Onxeo specializes in therapeutic agents for DNA Damage Response (DDR) in rare and resistant cancers, with promising compounds like AsiDNA™ and OX401 in its pipeline.
On December 31, 2021, ONXEO (ALONX) reported liquidity account resources as part of its contract with Kepler Cheuvreux. The account held 429,850 shares and €36,891.92. For the semester, there were 256 buy-side executions involving 357,510 shares and €179,383.26, alongside 155 sell-side executions for 221,580 shares and €115,071.34. In comparison, on June 30, 2021, the account had 293,920 shares and €101,406.22. The report complies with AMF Decision N°2021-01, which renews liquidity contracts as an accepted market practice.
Onxeo S.A. has appointed Julien Miara as interim CEO, effective January 3, 2022. Miara, with over 10 years in finance and biotechnology, aims to ensure the company aligns with its strategic plan during the CEO transition. The Board is also seeking a permanent CEO to expedite the development of AsiDNA and enhance international visibility. The company focuses on innovative oncology drugs targeting tumor DNA Damage Response, with promising studies ongoing for AsiDNA™ and OX401.
Onxeo S.A. (Euronext: ALONX, ONXEO) presented new preclinical data at the EACR-AstraZeneca Virtual Conference, demonstrating the unique antitumoral properties of AsiDNA™, a first-in-class DNA Damage Response inhibitor. The data highlights that AsiDNA™ can prevent the regrowth of drug-tolerant persister cells, which are a major barrier in cancer treatment. CEO Judith Greciet emphasized the significance of these findings in combating therapy resistance, paving the way for future combination strategies.
Onxeo S.A. has appointed Bryan Giraudo, COO & CFO of Gossamer Bio, as an independent member of its Board of Directors, replacing Thomas Hofstaetter. Giraudo brings extensive financial expertise and a strong network in the U.S. life sciences sector. His appointment aims to strengthen Onxeo's international focus, especially in developing its innovative oncology drug, AsiDNA™, which targets DNA Damage Response (DDR). Chairwoman Shefali Agarwal and CEO Judith Greciet lauded his financial acumen and strategic insights.
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO) has appointed
